Biogen Inc (BIIB) - Net Assets
Based on the latest financial reports, Biogen Inc (BIIB) has net assets worth $18.26 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.44 Billion) and total liabilities ($11.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BIIB financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $18.26 Billion |
| % of Total Assets | 62.01% |
| Annual Growth Rate | 14.73% |
| 5-Year Change | 66.58% |
| 10-Year Change | 50.53% |
| Growth Volatility | 55.96 |
Biogen Inc - Net Assets Trend (1985–2025)
This chart illustrates how Biogen Inc's net assets have evolved over time, based on quarterly financial data. Also explore Biogen Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Biogen Inc (1985–2025)
The table below shows the annual net assets of Biogen Inc from 1985 to 2025. For live valuation and market cap data, see BIIB stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $18.26 Billion | +9.22% |
| 2024-12-31 | $16.72 Billion | +12.95% |
| 2023-12-31 | $14.80 Billion | +10.54% |
| 2022-12-31 | $13.39 Billion | +22.16% |
| 2021-12-31 | $10.96 Billion | +2.56% |
| 2020-12-31 | $10.69 Billion | -19.89% |
| 2019-12-31 | $13.34 Billion | +2.36% |
| 2018-12-31 | $13.03 Billion | +3.44% |
| 2017-12-31 | $12.60 Billion | +3.87% |
| 2016-12-31 | $12.13 Billion | +29.37% |
| 2015-12-31 | $9.37 Billion | -13.31% |
| 2014-12-31 | $10.81 Billion | +25.44% |
| 2013-12-31 | $8.62 Billion | +23.80% |
| 2012-12-31 | $6.96 Billion | +8.35% |
| 2011-12-31 | $6.43 Billion | +17.94% |
| 2010-12-31 | $5.45 Billion | -12.97% |
| 2009-12-31 | $6.26 Billion | +7.85% |
| 2008-12-31 | $5.81 Billion | +4.91% |
| 2007-12-31 | $5.53 Billion | -22.59% |
| 2006-12-31 | $7.15 Billion | +3.53% |
| 2005-12-31 | $6.91 Billion | +1.16% |
| 2004-12-31 | $6.83 Billion | -3.22% |
| 2003-12-31 | $7.05 Billion | +342.10% |
| 2002-12-31 | $1.60 Billion | +18.28% |
| 2001-12-31 | $1.35 Billion | +21.91% |
| 2000-12-31 | $1.11 Billion | +12.95% |
| 1999-12-31 | $979.53 Million | +36.31% |
| 1998-12-31 | $718.61 Million | +34.00% |
| 1997-12-31 | $536.29 Million | +10.72% |
| 1996-12-31 | $484.37 Million | +26.47% |
| 1995-12-31 | $382.98 Million | +16.08% |
| 1994-12-31 | $329.93 Million | +1.46% |
| 1993-12-31 | $325.20 Million | +14.11% |
| 1992-12-31 | $285.00 Million | +19.25% |
| 1991-12-31 | $239.00 Million | +64.04% |
| 1990-12-31 | $145.70 Million | +4.67% |
| 1989-12-31 | $139.20 Million | +104.71% |
| 1988-12-31 | $68.00 Million | +0.15% |
| 1987-12-31 | $67.90 Million | -23.96% |
| 1986-12-31 | $89.30 Million | +19.23% |
| 1985-12-31 | $74.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2060650000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $20.55 Billion | 112.58% |
| Common Stock | $100.00K | 0.00% |
| Other Comprehensive Income | $-182.00 Million | -1.00% |
| Total Equity | $18.26 Billion | 100.00% |
Biogen Inc Competitors by Market Cap
The table below lists competitors of Biogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Amrize Ltd
NYSE:AMRZ
|
$27.46 Billion |
|
Sampo A SDB
ST:SAMPO-SDB
|
$27.48 Billion |
|
Hexagon AB (publ)
ST:HEXA-B
|
$27.49 Billion |
|
Ryanair Holdings plc
IR:RYA
|
$27.57 Billion |
|
ACS A.DE C.ADR 1/5/EO-50
F:OCI
|
$27.44 Billion |
|
ON Semiconductor Corporation
NASDAQ:ON
|
$27.40 Billion |
|
Teck Resources Limited
TO:TECK-B
|
$27.40 Billion |
|
Wiwynn Corp
TW:6669
|
$27.37 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,716,000,000 to 18,256,800,000, a change of 1,540,800,000 (9.2%).
- Net income of 1,293,389,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 45,800,000.
- Other factors increased equity by 293,211,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.29 Billion | +7.08% |
| Other Comprehensive Income | $-45.80 Million | -0.25% |
| Other Changes | $293.21 Million | +1.61% |
| Total Change | $- | 9.22% |
Book Value vs Market Value Analysis
This analysis compares Biogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.50x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1100.80x to 1.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.17 | $187.06 | x |
| 1986-12-31 | $0.19 | $187.06 | x |
| 1987-12-31 | $0.13 | $187.06 | x |
| 1988-12-31 | $0.28 | $187.06 | x |
| 1989-12-31 | $0.36 | $187.06 | x |
| 1990-12-31 | $0.27 | $187.06 | x |
| 1991-12-31 | $0.35 | $187.06 | x |
| 1992-12-31 | $0.33 | $187.06 | x |
| 1993-12-31 | $0.40 | $187.06 | x |
| 1994-12-31 | $0.40 | $187.06 | x |
| 1995-12-31 | $0.54 | $187.06 | x |
| 1996-12-31 | $0.52 | $187.06 | x |
| 1997-12-31 | $0.58 | $187.06 | x |
| 1998-12-31 | $0.76 | $187.06 | x |
| 1999-12-31 | $2.07 | $187.06 | x |
| 2000-12-31 | $2.39 | $187.06 | x |
| 2001-12-31 | $3.38 | $187.06 | x |
| 2002-12-31 | $4.00 | $187.06 | x |
| 2003-12-31 | $21.14 | $187.06 | x |
| 2004-12-31 | $19.87 | $187.06 | x |
| 2005-12-31 | $19.95 | $187.06 | x |
| 2006-12-31 | $20.71 | $187.06 | x |
| 2007-12-31 | $17.29 | $187.06 | x |
| 2008-12-31 | $19.68 | $187.06 | x |
| 2009-12-31 | $21.49 | $187.06 | x |
| 2010-12-31 | $21.17 | $187.06 | x |
| 2011-12-31 | $26.23 | $187.06 | x |
| 2012-12-31 | $29.04 | $187.06 | x |
| 2013-12-31 | $36.17 | $187.06 | x |
| 2014-12-31 | $45.60 | $187.06 | x |
| 2015-12-31 | $40.55 | $187.06 | x |
| 2016-12-31 | $55.43 | $187.06 | x |
| 2017-12-31 | $59.15 | $187.06 | x |
| 2018-12-31 | $63.51 | $187.06 | x |
| 2019-12-31 | $71.20 | $187.06 | x |
| 2020-12-31 | $66.34 | $187.06 | x |
| 2021-12-31 | $72.84 | $187.06 | x |
| 2022-12-31 | $91.77 | $187.06 | x |
| 2023-12-31 | $101.64 | $187.06 | x |
| 2024-12-31 | $114.57 | $187.06 | x |
| 2025-12-31 | $124.45 | $187.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.08%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.18%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.61x
- Recent ROE (7.08%) is below the historical average (11.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | -25.50% | -126.49% | 0.18x | 1.15x | $-26.59 Million |
| 1986 | -31.58% | -440.63% | 0.06x | 1.13x | $-37.13 Million |
| 1987 | -33.28% | -262.79% | 0.11x | 1.19x | $-29.39 Million |
| 1988 | -1.76% | -5.83% | 0.25x | 1.19x | $-8.00 Million |
| 1989 | 2.30% | 11.23% | 0.20x | 1.04x | $-10.72 Million |
| 1990 | 5.28% | 15.37% | 0.32x | 1.09x | $-6.87 Million |
| 1991 | 3.01% | 11.73% | 0.24x | 1.06x | $-16.70 Million |
| 1992 | 13.44% | 30.96% | 0.40x | 1.09x | $9.80 Million |
| 1993 | 9.96% | 23.75% | 0.38x | 1.10x | $-120.00K |
| 1994 | -1.48% | -3.13% | 0.41x | 1.15x | $-37.89 Million |
| 1995 | 1.48% | 3.73% | 0.32x | 1.23x | $-32.64 Million |
| 1996 | 8.37% | 14.63% | 0.44x | 1.31x | $-7.91 Million |
| 1997 | 16.63% | 20.54% | 0.53x | 1.52x | $35.54 Million |
| 1998 | 19.30% | 24.87% | 0.60x | 1.29x | $66.84 Million |
| 1999 | 22.51% | 27.75% | 0.62x | 1.30x | $122.50 Million |
| 2000 | 30.15% | 36.04% | 0.65x | 1.29x | $222.94 Million |
| 2001 | 20.22% | 26.16% | 0.61x | 1.28x | $137.80 Million |
| 2002 | 9.28% | 36.64% | 0.20x | 1.26x | $-11.45 Million |
| 2003 | -12.41% | -470.14% | 0.02x | 1.35x | $-1.58 Billion |
| 2004 | 0.37% | 1.57% | 0.17x | 1.34x | $-657.55 Million |
| 2005 | 2.33% | 9.38% | 0.20x | 1.21x | $-529.88 Million |
| 2006 | 3.04% | 8.11% | 0.31x | 1.20x | $-497.47 Million |
| 2007 | 11.53% | 20.12% | 0.37x | 1.56x | $84.74 Million |
| 2008 | 13.49% | 19.11% | 0.48x | 1.46x | $202.56 Million |
| 2009 | 15.59% | 22.16% | 0.51x | 1.37x | $347.98 Million |
| 2010 | 18.63% | 21.31% | 0.58x | 1.50x | $465.62 Million |
| 2011 | 19.21% | 24.45% | 0.56x | 1.41x | $591.73 Million |
| 2012 | 19.82% | 25.02% | 0.54x | 1.46x | $683.88 Million |
| 2013 | 21.60% | 26.86% | 0.58x | 1.38x | $1.00 Billion |
| 2014 | 27.14% | 30.25% | 0.68x | 1.32x | $1.85 Billion |
| 2015 | 37.84% | 32.95% | 0.55x | 2.08x | $2.61 Billion |
| 2016 | 30.53% | 32.34% | 0.50x | 1.89x | $2.49 Billion |
| 2017 | 20.15% | 20.69% | 0.52x | 1.88x | $1.28 Billion |
| 2018 | 33.98% | 32.93% | 0.53x | 1.94x | $3.13 Billion |
| 2019 | 44.13% | 40.96% | 0.53x | 2.04x | $4.55 Billion |
| 2020 | 37.39% | 29.76% | 0.55x | 2.30x | $2.93 Billion |
| 2021 | 14.28% | 14.17% | 0.46x | 2.19x | $466.48 Million |
| 2022 | 22.74% | 29.95% | 0.41x | 1.83x | $1.71 Billion |
| 2023 | 7.85% | 11.81% | 0.37x | 1.81x | $-318.84 Million |
| 2024 | 9.76% | 16.87% | 0.34x | 1.68x | $-39.40 Million |
| 2025 | 7.08% | 13.18% | 0.33x | 1.61x | $-532.29 Million |
Industry Comparison
This section compares Biogen Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $18,121,341,222
- Average return on equity (ROE) among peers: 33.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biogen Inc (BIIB) | $18.26 Billion | -25.50% | 0.61x | $27.45 Billion |
| AbbVie Inc (ABBV) | $4.49 Billion | 91.90% | 5.50x | $365.30 Billion |
| Amgen Inc (AMGN) | $25.78 Billion | 20.01% | 1.68x | $177.77 Billion |
| Amarin Corporation PLC (AMRN) | $667.10 Million | 1.16% | 0.60x | $292.71 Million |
| AstraZeneca PLC (AZN) | $23.95 Billion | 26.05% | 1.24x | $286.40 Billion |
| Bristol-Myers Squibb Company (BMY) | $12.21 Billion | 42.98% | 1.42x | $118.52 Billion |
| Gilead Sciences Inc (GILD) | $1.87 Billion | 24.02% | 0.15x | $163.34 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $8.32 Billion | 55.33% | 3.74x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $70.42 Billion | 23.49% | 1.01x | $547.37 Billion |
| Eli Lilly and Company (LLY) | $15.39 Billion | 15.53% | 1.36x | $862.20 Billion |
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more